Irving, TX & La Jolla, CA – June 19, 2017 – ExxonMobil and Synthetic Genomics Inc. today announced a breakthrough in joint research into advanced biofuels involving the modification of an algae strain that more than doubled its oil content without significantly inhibiting the strain’s growth.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2017-06-19 08:02:212018-04-20 14:15:18ExxonMobil and Synthetic Genomics Report Breakthrough in Algae Biofuel Research
San Diego, CA — June 1, 2017 — Synthetic Genomics, Inc. and Advaxis, Inc. (NASDAQ:ADXS) announced today that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the production of synthetic DNA constructs. The cGMP suite has been designed to meet cGMP Phase 1 clinical quality and manufacturing requirements mandated by the FDA.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2017-06-01 05:07:322018-04-20 14:15:49Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials
San Diego, CA — May 29, 2017 — Synthetic Genomics, Inc. announced today the publication of a peer reviewed article describing the development and operation of its digital-to-biological converter (DBC) prototype that produced biologic compounds on-demand without any human intervention. The DBC integrates many of the synthetic biology tools developed by Synthetic Genomics for creating high fidelity and complex synthetic DNA all in one fully automated unit.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2017-05-29 08:05:112018-04-20 14:16:16Digital-to-Biological Converter for On-Demand Production of Biologics Developed by Synthetic Genomics, Inc.
La Jolla, CA – January 18, 2017 – Synthetic Genomics, Inc. and ExxonMobil (NYSE: XOM) announced today that they have extended their agreement to conduct joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production.
San Diego, CA — January 9, 2017 — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble recombinant proteins faster and more efficiently than E. coli-based systems.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jnellishttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjnellis2017-01-09 17:55:272018-04-25 15:16:47Synthetic Genomics Launches Vmax™ Express, a Next-Generation Protein Expression Platform for the Biotech Industry
San Diego, CA — Jan. 5, 2017 — Synthetic Genomics, Inc., announced today that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics’ proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific infectious diseases. The deal was facilitated by Johnson & Johnson Innovation.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jnellishttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjnellis2017-01-08 08:05:292018-04-25 15:11:57Synthetic Genomics Announces Collaboration with Johnson & Johnson Innovation to Develop Novel Therapeutics Using Synthetic Genomics’ Replicon RNA Technology
La Jolla, CA – November 22, 2016 – Synthetic Genomics, Inc., announced today that Oliver Fetzer, Ph.D., chief executive officer, will present at two upcoming conferences.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2016-11-22 06:51:262018-04-25 15:12:15Synthetic Genomics to Present at Two Upcoming Investor Conferences
La Jolla, CA – November 9, 2016 – Synthetic Genomics, Inc., announced today that it has appointed industry veterans Tina Nova, Ph.D., and William McKee to its board of directors.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2016-11-09 07:04:422018-04-25 15:12:47Synthetic Genomics Appoints Tina Nova, Ph.D., and William McKee to Board of Directors
La Jolla, CA – August 29, 2016 – Researchers from Synthetic Genomics, Inc. (SGI) announced today the development and extensive engineering of Vibrio natriegens into a next-generation biotechnology host organism Vmax™. Looking to accelerate the pace of discovery and the path to sustainable solutions, the team set out to develop a novel bacterial host that will drastically reduce the amount of time scientists spend on each experiment and workflow and to enhance productivity of the resulting new host.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2016-08-29 21:39:202018-04-25 15:13:01Synthetic Genomics team engineers Vmax™, an advantaged next-generation host organism for a wide range of biotechnology applications
La Jolla, CA — August 4, 2016 — Researchers from the J. Craig Venter Institute (JCVI) and Synthetic Genomics, Inc. (SGI) have published research describing a method for engineering Mycoplasma mycoides 16S ribosomal RNA (rRNA) using a one-step process that combines CRISPR/Cas9 gene editing system with yeast recombination machinery.
https://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.png00jcalhoonhttps://syntheticgenomics.com/wp-content/uploads/SGI_logo0293746.pngjcalhoon2016-08-04 21:44:052018-04-25 15:13:24Teams at Venter Institute and Synthetic Genomics, Inc. Successfully Engineer 16S rRNA using One Step Process Combining CRISPR/Cas9 Systems and Yeast Recombination Machinery
ExxonMobil and Synthetic Genomics Report Breakthrough in Algae Biofuel Research
/in Press Releases /by jcalhoonIrving, TX & La Jolla, CA – June 19, 2017 – ExxonMobil and Synthetic Genomics Inc. today announced a breakthrough in joint research into advanced biofuels involving the modification of an algae strain that more than doubled its oil content without significantly inhibiting the strain’s growth.
Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials
/in Press Releases /by jcalhoonSan Diego, CA — June 1, 2017 — Synthetic Genomics, Inc. and Advaxis, Inc. (NASDAQ:ADXS) announced today that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the production of synthetic DNA constructs. The cGMP suite has been designed to meet cGMP Phase 1 clinical quality and manufacturing requirements mandated by the FDA.
Digital-to-Biological Converter for On-Demand Production of Biologics Developed by Synthetic Genomics, Inc.
/in Press Releases /by jcalhoonSan Diego, CA — May 29, 2017 — Synthetic Genomics, Inc. announced today the publication of a peer reviewed article describing the development and operation of its digital-to-biological converter (DBC) prototype that produced biologic compounds on-demand without any human intervention. The DBC integrates many of the synthetic biology tools developed by Synthetic Genomics for creating high fidelity and complex synthetic DNA all in one fully automated unit.
Synthetic Genomics and ExxonMobil Renew Algae Biofuels Research Agreement
/in Press Releases /by jnellisLa Jolla, CA – January 18, 2017 – Synthetic Genomics, Inc. and ExxonMobil (NYSE: XOM) announced today that they have extended their agreement to conduct joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production.
Synthetic Genomics Launches Vmax™ Express, a Next-Generation Protein Expression Platform for the Biotech Industry
/in Press Releases /by jnellisSan Diego, CA — January 9, 2017 — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble recombinant proteins faster and more efficiently than E. coli-based systems.
Synthetic Genomics Announces Collaboration with Johnson & Johnson Innovation to Develop Novel Therapeutics Using Synthetic Genomics’ Replicon RNA Technology
/in Press Releases /by jnellisSan Diego, CA — Jan. 5, 2017 — Synthetic Genomics, Inc., announced today that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics’ proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific infectious diseases. The deal was facilitated by Johnson & Johnson Innovation.
Synthetic Genomics to Present at Two Upcoming Investor Conferences
/in Press Releases /by jcalhoonLa Jolla, CA – November 22, 2016 – Synthetic Genomics, Inc., announced today that Oliver Fetzer, Ph.D., chief executive officer, will present at two upcoming conferences.
Synthetic Genomics Appoints Tina Nova, Ph.D., and William McKee to Board of Directors
/in Press Releases /by jcalhoonLa Jolla, CA – November 9, 2016 – Synthetic Genomics, Inc., announced today that it has appointed industry veterans Tina Nova, Ph.D., and William McKee to its board of directors.
Synthetic Genomics team engineers Vmax™, an advantaged next-generation host organism for a wide range of biotechnology applications
/in Press Releases /by jcalhoonLa Jolla, CA – August 29, 2016 – Researchers from Synthetic Genomics, Inc. (SGI) announced today the development and extensive engineering of Vibrio natriegens into a next-generation biotechnology host organism Vmax™. Looking to accelerate the pace of discovery and the path to sustainable solutions, the team set out to develop a novel bacterial host that will drastically reduce the amount of time scientists spend on each experiment and workflow and to enhance productivity of the resulting new host.
Teams at Venter Institute and Synthetic Genomics, Inc. Successfully Engineer 16S rRNA using One Step Process Combining CRISPR/Cas9 Systems and Yeast Recombination Machinery
/in Press Releases /by jcalhoonLa Jolla, CA — August 4, 2016 — Researchers from the J. Craig Venter Institute (JCVI) and Synthetic Genomics, Inc. (SGI) have published research describing a method for engineering Mycoplasma mycoides 16S ribosomal RNA (rRNA) using a one-step process that combines CRISPR/Cas9 gene editing system with yeast recombination machinery.